Study Summary
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).
Want to learn more about this trial?
Request More InfoInterventions
CD19-CAR_Lenti_ALLODRUG
Biological/Vaccine: CD19-CAR\_Lenti\_ALLO
A single infusion of CD19-CAR\_Lenti\_ALLO on Day 0
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ospedale Pediatrico Bambino Gesù | Rome | Italy | Italy |